News roundup Tuesday, November 12

announces that ALG.APV-527 meets key milestones in Phase I study in solid tumors. Read more.

AstraZeneca Investing $3,5 billion in R&D and manufacturing in the US. Read more. The company reports milestones with datopotamab deruxtecan and the phase III KOMET study, read more here and here.

Kancera decides to focus its operations on cardiovascular diseases. Read more.

Saniona Update on the tesofensine application. Read more.

Optomed receives an order of 1,5 million USD and raises its full-year outlook. Read more.

SciBase decides on a directed new share issue of approximately SEK 22,5 million and a rights issue of up to approximately SEK 59,3 million. Read more.

Vivestos Paccal Vet receives Limited Market classification in the EU. Read more.

SmartCella New European patent granted for Extroducer delivery platform. Read more.

CS MEDICA updates on the strategic rationale behind CANNORDIC's IPO and capital raising. Read more.

Herantis Pharma has successfully completed part I of the Phase Ib clinical study. Read more.

Abera Bioscience initiates in vivo studies for its new nasal influenza candidate. Read more.

ADDvise receives orders worth USD 1,8 million. Read moreThe company is investigating the possibility of divesting the subsidiary. Germa. Read more.

Bio Vitos Pharma agreement is entered into to divest Home check. Read more.

Alteco Medical receives a loan from the principal owner. Read more.

VibroSense has signed a distribution agreement with LifeMed OY in Finland. Read more.

Today is the last day for trading in the warrants of series TO6 in Lumito. Read more.

Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025. Read more.

ViroGates Capital raising of 8,2 MDKK has been registered. Read more.

Cellevate is holding a global launch webinar for Cellevat3d on November 27th. Read more.